WHO Closer To FDA Approval For Malaria Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has been holding the world body to the same standards it uses for a regular drug review, resulting in many years of delay in bringing artesunate rectal suppositories to market - but the Anti-Infective Drugs Advisory Committee has given a partial endorsement.
You may also be interested in...
Amivas’ Malaria Drug Approval Brings Orphan Exclusivity, But Priority Review Voucher Status Unclear
Amivas requested a US tropical disease PRV for intravenous artesunate but FDA has not yet made a decision on eligibility; approval appears to block La Jolla’s competing product, currently under review, for seven years.
Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says
J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee
Synthetic Cell Technology Could Benefit Vaccine Production, Venter Says
J. Craig Venter's synthetic cell may dramatically speed up vaccine production, he told a Congressional committee
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: